Viking Therapeutics, Inc. (NASDAQ:VKTX) Q3 2022 Earnings Conference Call October 26, 2022 4:30 PM ET

Company Participants

Stephanie Diaz - Manager, Investor Relations

Brian Lian - President & Chief Executive Officer

Greg Zante - Chief Financial Officer

Conference Call Participants

Steve Seedhouse - Raymond James

Joon Lee - Truist

Andy Hsieh - William Blair

Thomas Smith - SVB Securities

Yale Jen - Laidlaw

Scott Henry - ROTH Capital

Justin Zelin - BTIG

Naz Rahman - Maxim Group

Operator

Welcome to the Viking Therapeutics' 2022 Third Quarter Financial Results Conference Call. At this time, all participants are in listen-only mode. Following management's prepared remarks, we will hold a Q&A session. [Operator instructions] As a reminder, this conference call is being recorded today, October 26, 20221.

I would now like to turn the conference over to Viking's Manager of Investor Relations, Stephanie Diaz. Please go ahead, Stephanie.

Stephanie Diaz

Hello and thank you all for participating in today's call. Joining me today is Brian Lian, Viking's President and CEO; and Greg Zante, Viking's CFO.

Before we begin, I'd like to caution that comments made during this conference call today, October 26, 2022, will contain forward-looking statements under the Safe Harbor provisions of the US Private Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its development activities, timelines and milestones.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely and reported results should not be considered as an indication of future performance. These forward-looking statements speak only as of today's date and the company undertakes no obligation to revise or update any statement made today. I encourage you to review all of the company's filings with the Securities and Exchange Commission concerning these and other matters.

I'll now turn the call over to Brian Lian for his initial comments.

Brian Lian

Thanks Stephanie. And thank you to everyone dialed in by phone or listening on the webcast. Today, we'll review our financial results for the third quarter of 2022 and provide an update on recent progress with our pipeline programs and operations.

Through the first three quarters of 2022, we made solid progress with each of our clinical programs. With respect to our lead candidate, VK2809 for the treatment of NASH and fibrosis, in the third quarter, we continued enrolling patients in the Phase IIb VOYAGE study and expect to complete enrollment in this trial by year end.